Australia - English - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - powder for infusion - 2 g - active: ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 0.596 g equivalent to ceftriaxone 0.5g - powder for injection - 0.5 g - active: ceftriaxone sodium 0.596 g equivalent to ceftriaxone 0.5g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenindione -

Australia - English - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: xanthan gum; hypromellose; silicon dioxide; saccharin sodium; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; flavour - amoklavin duo 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoklavin duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoklavin duo 400/57, should not require the addition of another antibiotic due to the amoxicillin content of amoklavin duo 400/57.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - phytomenadione, quantity: 10 mg/ml - injection, solution - excipient ingredients: glycocholic acid; lecithin; sodium hydroxide; hydrochloric acid; water for injections - prophylaxis and treatment of haemorrhagic disease of the newborn. indications as at 18 october 2000: prophylaxis and treatment of vitamin k deficiency bleeding (vkdb).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - phytomenadione, quantity: 10 mg/ml - solution - excipient ingredients: hydrochloric acid; glycocholic acid; water for injections; lecithin; sodium hydroxide - haemorrhage or threatened haemorrhage as a result of severe "hypo-prothrombinaemia" (i.e. deficiency of coagulation factors ii, vii, ix and x) due, for instance, to overdosage of anticoagulants of the dicoumarol type, or to other forms of hypovitaminosis k (e.g. obstructive jaundice, liver and intestinal disorders or prolonged administration of antibiotics, sulfonamides or salicylates).

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - benzydamine hydrochloride 0.15%{relative}; chlorhexidine gluconate 0.12%{relative};  ;   - gargle - active: benzydamine hydrochloride 0.15%{relative} chlorhexidine gluconate 0.12%{relative}     excipient: ethanol glycerol hydrochloric acid peppermint flavour p0551 957685 polysorbate 20 purified water saccharin sodium sodium bicarbonate - for relief of painful conditions of the throat and mouth

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - benzydamine hydrochloride 0.15%{relative}; chlorhexidine gluconate 0.12%{relative};  ;   - oral spray - active: benzydamine hydrochloride 0.15%{relative} chlorhexidine gluconate 0.12%{relative}     excipient: ethanol glycerol hydrochloric acid peppermint flavour p0551 957685 polysorbate 20 purified water saccharin sodium sodium bicarbonate - for relief of painful conditions of the throat